MOTS-c

Also: Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide (MDP), MOTSc, MOTS-C

Mitochondrial / mitochondrial-derived peptidePreliminaryPredominantly preclinical. The current literature consists largely of in vitro (cell-culture) experiments and animal (mostly rodent) models, with limited and early-stage human observational data. MOTS-c is described as an investigational research compound and is not an approved drug or therapy. Reported mechanisms and associations remain under active study and have not been established in humans.

This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more

This entry is a draft pending editorial and source verification. It is excluded from search indexing until reviewed.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondrial-derived peptide that appears in the research literature primarily as a molecule discussed in the context of cellular metabolism and the stress response. The available evidence is largely preclinical, drawn from in vitro systems and animal models, with limited human data. This profile summarizes how MOTS-c is described in the scientific literature for research and documentation purposes only; it does not describe or imply any therapeutic use, benefit, safety, or outcome, and is not a recommendation for use in humans or animals. Findings should be interpreted cautiously given study-design and translation limitations.

Mechanism as described in the literature

MOTS-c is a short peptide encoded within the mitochondrial 12S ribosomal RNA region and belongs to a class of molecules described in the literature as mitochondrial-derived peptides (MDPs). In vitro and animal studies characterize it as a putative signaling peptide that has been reported to distribute between the cytosol and, under certain metabolic-stress conditions, the nucleus, where mechanistic work has described associations with the regulation of nuclear gene expression. These are descriptive, preclinical observations rather than established functions in human physiology.

Reported mechanisms in preclinical models center on metabolic signaling pathways, including descriptions involving AMP-activated protein kinase (AMPK) activity and the folate-methionine one-carbon metabolic pathway. These mechanistic accounts derive chiefly from cell-culture and rodent systems and have not been clearly established in humans; the pathways and their physiological relevance remain an active area of investigation and require careful interpretation due to study-design and translation limitations.

Research areas

Cellular metabolism and glucose-related signaling (preclinical: in vitro and rodent models)
Mitochondrial biology and the cellular stress response (mechanistic)
Skeletal-muscle and exercise-physiology signaling (animal models)
Aging-related cellular signaling and mitochondrial-nuclear communication (mechanistic)
Regulation of nuclear gene expression under metabolic stress (in vitro)

Known limitations

The evidence base is predominantly preclinical (rodent and cell-culture); robust, controlled human data are limited.
Pharmacokinetics, bioavailability, and stability of exogenous MOTS-c are not well characterized in the literature.
Mechanistic findings (e.g., AMPK and one-carbon-metabolism associations) come largely from in vitro systems and may not translate to whole-organism or human physiology.
Endogenous (naturally produced) MOTS-c biology may differ substantially from any exogenously administered peptide, complicating interpretation.
Assay variability, differing model systems, and small study sizes make cross-study comparison and generalization difficult.
No claims of safety, efficacy, or therapeutic benefit can be drawn from the current literature; results require independent editorial and source verification.

Documentation notes

References

References for this entry are pending editorial verification. We do not publish citations we have not confirmed.

Frequently asked questions

What is MOTS-c?+

MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. In the research literature it is discussed mainly as a putative metabolic-signaling peptide. It is described as an investigational research compound, not an approved therapy, and this profile makes no human- or animal-use recommendation.

What does the research literature say about MOTS-c?+

Preclinical (in vitro and animal) studies describe associations with metabolic signaling pathways, including AMPK activity and folate-methionine one-carbon metabolism, and report movement to the nucleus under metabolic stress. These are mechanistic, early-stage observations that have not been established in humans and should be interpreted cautiously.

Is the evidence for MOTS-c strong?+

No. The evidence is preliminary and largely preclinical, with limited human data. Pharmacokinetics and translation to human physiology remain poorly characterized, so no conclusions about real-world effects, safety, or benefit can be drawn from the current literature.